Posts by: Ana Pamplona, PhD

Ana Pamplona, PhD

Ana holds her PhD in Biochemistry from the Faculty of Science and Technology from Lisbon (UNL). She has worked in the T-cell differentiation and Tumor targeting Lab at Instituto de Medicina Molecular, headed by Prof. Bruno Silva-Santos, and has served as a scientific reviewer for the peer-reviewed journal Infection & Immunity.

December 10, 2014December 10, 2014

Researchers Optimize New Lung Cancer Risk Model

Lung Cancer, News

A new study established a model to predict the risk of lung cancer entitled “Evaluation of the Lung Cancer Risks at Which to Screen Ever- and Never-Smokers: Screening Rules Applied ... Read more

December 8, 2014November 6, 2015

Inhaled Aztreonam Shows Positive Results For Non-Cystic Fibrosis Bronchiectasis Patients In Recent Phase 3 Trials

Bronchiectasis, News

A study from a Phase 3 trial on an inhaled antibiotic therapy for non-cystic fibrosis bronchiectasis entitled “Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): ... Read more

December 5, 2014December 5, 2014

Changing Diet May Lower Lung Cancer Risk

Lung Cancer, News

A new study on the association between diet and lung cancer entitled “Nutrition and lung cancer: a case control study in Iran” was recently published in BMC Cancer by Mostafa ... Read more

December 5, 2014November 11, 2015

Observational Arterial Pressure Monitoring Includes COPD Parameters

COPD, News

A new study entitled “Accuracy of invasive arterial pressure monitoring in cardiovascular patients: an observational study” was published in Critical Care by Dr. Stefano Romagnoli, part of Dr. A Raffaele ... Read more

December 2, 2014November 11, 2015

Positive Data For Drug That Treats Treatment-Refractory Chronic Cough

COPD, News

A new publication from Afferent Pharmaceuticals’ Phase 2 clinical trial results entitled “P2X3 Receptor Antagonist (AF-219) in Refractory Chronic Cough: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study” was published in ... Read more

December 2, 2014November 6, 2015

Bayer’s Non-cystic Fibrosis Bronchiectasis, Pneumonia Drugs Gain QIDP Status From FDA

Bronchiectasis, News

Recently, two Bayer experimental drugs, Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation (DPI), were granted the title of qualified infectious disease products (QIDP) by the U.S. Food and Drug Administration ... Read more

November 26, 2014November 5, 2015

Natural Chronic Protein Misfolding Responses in CF Lead To Increased Health Issues

Cystic Fibrosis, News

A new study about diseases such as Cystic Fibrosis that are associated with “Protein misfolding” entitled “Modulation of the Maladaptive Stress Response to Manage Diseases of Protein Folding” was published ... Read more

November 26, 2014November 5, 2015

CHMP Publishes Positive Opinion of Nintedanib IPF Drug

Idiopathic Pulmonary Fibrosis, News

Nintedanib, Boehringer Ingelheim’s treatment for patients with idiopathic pulmonary fibrosis (IPF), recently received positive opinions from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ... Read more

November 25, 2014November 11, 2015

Lung Disease Patients Have Higher Incidence of Inflammatory Bowel Disease

COPD, News

A new study entitled “Increased incidence of inflammatory bowel disease in Quebec residents with airway diseases” revealing that patients with airway diseases have a higher frequency of inflammatory bowel disease ... Read more

November 19, 2014November 6, 2015

Intravenous Antibiotics For Bronchiectasis Administered at Home Shows Promising Results

Bronchiectasis, News

A new prospective cohort study on the use of domiciliary intravenous (IV) antibiotic therapy in patients with non-cystic fibrosis bronchiectasis entitled “A prospective cohort study of the use of domiciliary ... Read more